Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Safety Study of E/C/F/TAF in HIV-1 Positive Patients with Mild to Moderate Renal Impairment
2013-000516-25Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Change from baseline in renal parameters at Week 24. Started Apr 2013; status: completed.
02
Drugs
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-000516-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000516-25.